Targeting key regulators in advanced prostate cancer that resist standard treatments
Official title: Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers
Funded at State University of New York at Buffalo · NIH-11159586 · Data updated 2026-11-12
This research looks for new ways to treat advanced prostate cancer that has stopped responding to common hormone therapies.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project start | August 10, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $541,248 |
| NIH project number | 5R37CA272726-03 |
| Project ID | NIH-11159586 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is relevant for patients with advanced castrate-resistant prostate cancer (CRPC) who have developed resistance to AR-targeted therapies.
✕Less likely to help
Patients whose prostate cancer has not yet become resistant to standard AR-targeted therapies may not directly benefit from this specific approach.
What this research studies
Many men with advanced prostate cancer eventually find that their hormone-blocking medicines, like enzalutamide, stop working. This happens because the cancer cells learn to use a different pathway, called non-canonical AR activity, to keep growing. Our team has identified specific "master switch" proteins that seem to control this new pathway, making the cancer resistant. We are working to understand how these master switches work and develop new treatments that can block them, potentially making existing therapies effective again.
Why it matters
Potential benefit: If successful, this work could lead to new treatments for advanced prostate cancer that has become resistant to current hormone therapies, offering more options for patients.
How similar studies have gone: Preliminary data in preclinical models suggests that suppressing these master factors can reverse acquired resistance, indicating a promising, though early, approach.
Where this research is happening
-
State University of New York at Buffalo
Amherst, United States Active
Researchers
- Principal investigator: Adelaiye-Ogala, Remi — State University of New York at Buffalo
- Study coordinator: Adelaiye-Ogala, Remi
Related research
Other NIH-funded projects on the same topics.
-
Ariginine-depleting therapy plus chemotherapy for aggressive variant prostate cancers
This project tests whether removing arginine from the body enhances chemotherapy for men with a difficult-to-treat prostate cancer subtype.
-
Targeting master regulators to overcome AR-driven resistance in advanced prostate cancer
This grant explores how cancer cells rewire their growth signals to resist AR-targeted therapies in advanced prostate cancer and tests new ways to block those master regulators.
-
Lowering arginine with chemotherapy for aggressive prostate cancer
Looks at whether lowering a nutrient called arginine together with platinum‑taxane chemotherapy can help men with aggressive, treatment‑resistant prostate cancer.
-
Investigating the impact of arginine depletion with chemotherapy in aggressive prostate cancers
This study is looking at how lowering levels of an amino acid called arginine might make chemotherapy work better for men with aggressive prostate cancer that doesn't respond well to regular treatments.
-
Targeting DNA repair pathways in prostate cancer
This study is looking at whether a special combination of treatments can help men with non-castrate prostate cancer, especially those with certain genetic changes, by focusing on fixing DNA damage to improve their chances of recovery.
-
Targeting key factors in advanced prostate cancer treatment resistance
This study is looking at how certain proteins in prostate cancer cells help the cancer resist treatments that target hormones, with the goal of finding new ways to improve treatment for patients who aren't responding to current therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.